Liquidia (LQDA) Cash from Financing Activities (2020 - 2026)
Liquidia's (LQDA) quarterly Cash from Financing Activities came in at -$18.1 million in Q1 2026, down 174.33% year-on-year from $24.3 million in Q1 2025, and down 157.11% quarter-over-quarter from -$7.0 million in Q4 2025.
Liquidia (LQDA) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Liquidia's Cash from Financing Activities history runs 7 years deep, the most recent figure standing at -$18.1 million for Q1 2026.
- On a quarterly basis, Cash from Financing Activities fell 174.33% year-over-year to -$18.1 million in Q1 2026; TTM through Mar 2026 was $17.4 million, a 85.43% decrease from a year earlier, with the FY2025 full-year figure at $59.7 million, down 69.32% from the prior year.
- Cash from Financing Activities fell to -$18.1 million in Q1 2026 per LQDA's latest filing, from -$7.0 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $99.7 million in Q1 2024 and bottomed at -$18.1 million in Q1 2026.
- The 5-year median for Cash from Financing Activities is $10.0 million (2023), against an average of $20.3 million.
- Across the five-year window, Cash from Financing Activities surged 41377.19% in 2023 and tumbled 205.84% in 2025, its largest moves.
- Year by year, Cash from Financing Activities stood at $57000.0 in 2022, then jumped by 41377.19% to $23.6 million in 2023, then plunged by 109.71% to -$2.3 million in 2024, then tumbled by 205.84% to -$7.0 million in 2025, then tumbled by 157.11% to -$18.1 million in 2026.
- Per Business Quant, the three latest LQDA Cash from Financing Activities figures stand at -$18.1 million (Q1 2026), -$7.0 million (Q4 2025), and -$5.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -840.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -494.13 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -1.48 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -203.80 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -86.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -65.00 Mn |
| 10 | Liquidia | 7.84 Bn | 7.61 Bn | 121.79 Mn | -18.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.05 Mn |
| Mar 31, 2026 | -18.05 Mn |
| Dec 31, 2025 | -7.02 Mn |
| Dec 31, 2025 | -7.02 Mn |
| Sep 30, 2025 | -5.25 Mn |
| Sep 30, 2025 | -5.25 Mn |
| Jun 30, 2025 | 47.71 Mn |
| Jun 30, 2025 | 47.71 Mn |
| Mar 31, 2025 | 24.29 Mn |
| Mar 31, 2025 | 24.29 Mn |
| Dec 31, 2024 | -2.30 Mn |
| Dec 31, 2024 | -2.30 Mn |
| Sep 30, 2024 | 98.10 Mn |
| Sep 30, 2024 | 98.10 Mn |
| Jun 30, 2024 | -814,000.00 |
| Jun 30, 2024 | -814,000.00 |
| Mar 31, 2024 | 99.67 Mn |
| Mar 31, 2024 | 99.67 Mn |
| Dec 31, 2023 | 23.64 Mn |
| Dec 31, 2023 | 23.64 Mn |